DE-THE-LYCRA-COMPANY
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that it is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. The LYCRA Company Pavilion in Hall 4.1 (Booth E56) features 931 square meters of exhibit space and 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827097449/en/
The LYCRA Company is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. Its pavilion in Hall 4.1 (Booth E56) features 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.” Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how bio-derived LYCRA® fiber made with QIRA® can help accelerate decarbonization in the fashion industry. (Photo: Business Wire)
The LYCRA Company will highlight products designed to meet consumer needs and help reduce the environmental impact of apparel products:
- Bio-derived LYCRA® fiber made with QIRA®, the industry’s first renewable spandex available at scale, will launch in the first half of 2025. Made from annually grown field corn, it's expected to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* while delivering equivalent performance to the original fiber. Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how this patented innovation can help accelerate decarbonization in the fashion industry.
- LYCRA® FiT400™ fiber is a unique bicomponent fiber engineered to optimize the comfort and performance of knits while delivering a durable, soft hand feel, all-day stretch, long-lasting fit, and cooling comfort. This Global Recycled Standard-certified fiber contains 60% recycled PET and 14.4% bio-derived resources.
- COOLMAX® EcoMade fiber made from 100% textile waste delivers cool and dry comfort to various garment types, while THERMOLITE® EcoMade fiber made from 100% textile waste adds lightweight warmth.
“We are thrilled to showcase our sustainable solutions at Intertextile that will help our customers reduce their carbon footprint and support their sustainability goals,” said Jason Wang, vice president, Asia. “We look forward to helping attendees find the consumer-driven, market-relevant branded solutions they need to take their business to the next level.”
The LYCRA Company will also showcase LYCRA® ADAPTIV fiber, one of the company’s fastest-growing products. Brands and retailers worldwide appreciate how it enables inclusive sizing and delivers a second-skin fit, enhanced comfort in motion, and greater functionality to activewear, intimate apparel, denim, and more. Regina Miracle, a leading garment maker and a key value chain partner of The LYCRA Company, will exhibit garment samples.
The booth will also feature garment samples of new LYCRA FitSense® denim technology, a targeted shaping innovation for stretch denim to deliver a customizable fit to different body types and shapes, a breakthrough for the industry launched this year. Through a combination of fiber, fabric, and garment processing technologies, this discreet and invisible solution retains the authentic denim look and feel that consumers desire.
To learn more about The LYCRA Company’s latest innovations and commitment to a more sustainable future, visit Intertextile Booth E56 in Hall 4.1 and Booth A36 in Hall 5.1, or visit this website.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA® FiT400™, LYCRA FitSense®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827097449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
